| 14 | 76 | Male | Megaloblastic Anemia | WBC: 2.83 × 109/L N (37.5%), L (50.5%) | RBC: 1.45 × 1012/L Hb: 64 g/L MCV: 125.5 fl RET%: 3.94 | 77 × 109/L |
| 15 | 65 | Male | Myelodysplastic Syndrome | WBC: 2.14 × 109/L N (49.5%), L (48.6%) | RBC: 1.5 × 1012/L Hb: 61 g/L MCV: 112 fl RET%: 2.44 | 25 × 109/L |
| 16 | 49 | Female | Megaloblastic Anemia | WBC: 1.71 × 109/L N (48.6%), L (45.6%) | RBC: 1.73 × 1012/L Hb: 60 g/L MCV: 105.8 fl RET%: 0.78 | 52 × 109/L |
| 17 | 34 | Female | Aplastic Anemia | WBC: 3.38 × 109/L N (42.9%), L (49.7%) | RBC: 2.87 × 1012/L Hb: 105 g/L MCV: 106.3 fl RET%: 1.92 | 14 × 109/L |
| 18 | 51 | Male | Non Hodgkin’s Lymphoma | WBC: 2.1 × 109/L N (40%), L (36.7%) | RBC: 2.37 × 1012/L Hb: 76 g/L MCV: 91.6 fl RET%: 1.44 | 38 × 109/L |
| 19 | 51 | Female | Hemophagocytic Syndrome | WBC: 0.38 × 109/L N (0.04%), L (44.74%) | RBC: 2.57 × 1012/L Hb: 77 g/L MCV: 80.2 fl RET%: 0.32 | 47 × 109/L |
| 20 | 58 | Male | Aplastic Anemia | WBC: 0.48 × 109/L N (20.84%), L (64.64%) | RBC: 2.19 × 1012/L Hb: 64 g/L MCV: 90.9 fl RET%: 0.45 | 75 × 109/L |
| 21 | 71 | Male | Myelodysplastic Syndrome | WBC: 2.37 × 109/L N (45.24%), L (42.24%) | RBC: 1.92 × 1012/L Hb: 61 g/L MCV: 93.8 fl RET%: 0.61 | 77 × 109/L |
| 22 | 60 | Male | Megaloblastic Anemia | WBC: 1.65 × 109/L N (64.9%), L (33.9%) | RBC: 1.24 × 1012/L Hb: 59 g/L MCV: 136.3 fl RET%: 0.68 | 35 × 109/L |
| 23 | 24 | Male | Non Hodgkin’s Lymphoma | WBC: 1.45 × 109/L N (49.6%), L (33.8%) | RBC: 2.85 × 1012/L Hb: 84 g/L MCV: 80.7 fl RET%: 1.29 | 33 × 109/L |
| 24 | 15 | Female | Systemic Lupus Erythematous | WBC: 1.38 × 109/L N (45.7%), L (44.2%) | RBC: 2.14 × 1012/L Hb: 67 g/L MCV: 93.5 fl RET%: 4.51 | 30 × 109/L |
| 25 | 60 | Female | Aplastic Anemia | WBC: 1.97 × 109/L N (20.3%), L (70.6%) | RBC: 2.63 × 1012/L Hb: 90 g/L MCV: 99.2 fl RET%: 1.43 | 14 × 109/L |